umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
2018 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 8, article id 17259Article in journal (Refereed) Published
Abstract [en]

Prostate cancer (PC) represents the second highest cancer-related mortality among men and the call for biomarkers for early discrimination between aggressive and indolent forms is essential. Downregulation of Regulator of G-protein signaling 2 (RGS2) has been shown in PC, however the underlying mechanism has not been described. Aberrant RGS2 expression has also been reported for other carcinomas in association to both positive and negative prognosis. In this study, we assessed RGS2 expression during PC progression in terms of regulation and impact on tumour phenotype and evaluated its prognostic value. Our experimental data suggest that the RGS2 downregulation seen in early PC is caused by hypoxia. In line with the common indolent phenotype of a primary PC, knockdown of RGS2 induced epithelial features and impaired metastatic properties. However, increased STAT3, TWIST1 and decreased E-cadherin expression suggest priming for EMT. Additionally, improved tumour cell survival and increased BCL-2 expression linked decreased RGS2 levels to fundamental tumour advantages. In contrast, high RGS2 levels in advanced PC were correlated to poor patient survival and a positive metastatic status. This study describes novel roles for RGS2 during PC progression and suggests a prognostic potential discriminating between indolent and metastatic forms of PC.

Place, publisher, year, edition, pages
Nature Publishing Group, 2018. Vol. 8, article id 17259
National Category
Cell and Molecular Biology
Identifiers
URN: urn:nbn:se:umu:diva-154045DOI: 10.1038/s41598-018-35332-4ISI: 000450911800030PubMedID: 30467386OAI: oai:DiVA.org:umu-154045DiVA, id: diva2:1272712
Funder
Swedish Cancer Society, CAN 2017/380Swedish Cancer Society, CAN 2017/478Region Västra Götaland, ALFGBG-138351Available from: 2018-12-19 Created: 2018-12-19 Last updated: 2018-12-19Bibliographically approved

Open Access in DiVA

fulltext(10070 kB)55 downloads
File information
File name FULLTEXT01.pdfFile size 10070 kBChecksum SHA-512
52888a54aad68a1b90dfc8b9bce92615d6851171b0da0b7e0b85ed3a65642c07aa960a6a1ef2f269cc857bd755b8519dd6df5e4fe42d1ab30ec5003ab0d726db
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Hagberg Thulin, Malin

Search in DiVA

By author/editor
Hagberg Thulin, Malin
By organisation
Oncology
In the same journal
Scientific Reports
Cell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 55 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 92 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf